Join
Live feed
·
INSIDERFilingvia Quantisnow
Amicus Therapeutics Inc. logo

Director Kelly Michael Aaron returned $1,050,786 worth of shares to the company (72,468 units at $14.50), closing all direct ownership in the company (SEC Form 4)

ByQuantisnow·Wall Street's wire, on your screen.
FOLD· Amicus Therapeutics Inc.
Health Care
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track FOLD (Amicus Therapeutics Inc.) and more on Quantisnow.